

Media Release

Zug, 18 May 2018

HBM Healthcare Investments reports a profit of CHF 115.9 million for the 2017/2018 financial year; Portfolio will be enriched with further new investments; Positive outlook for the portfolio allows for a 20 percent increase of the proposed cash dividend to a total of CHF 7.00 per share.

In the financial year just ended HBM Healthcare Investments continued along its successful path. The Company closed the 2017/2018 reporting period with a profit for the sixth successive year. The CHF 116 million surplus will be used for a number of new investments, as well as for an attractive cash dividend of CHF 7.00 per share (+ 20 percent). The long-term commitment to reducing the discount has also paid off, with the difference between share price and net asset value having contracted to just over ten percent.

With its strong innovative drive, the healthcare market continues to offer appealing investment opportunities. During the reporting year, HBM Healthcare Investments' engaged in three larger investments in companies with attractive risk profiles (Amicus, Harmony Biosciences, and Y-mAbs), rounded out by ten smaller investments in companies with promising clinical development programmes.

The major holdings in the portfolio of private companies are developing positively, and HBM Healthcare Investments expects to realise significant added value from these investments in the coming years as a result of IPOs or trade sales.

Review of the 2017/2018 financial year

Net asset value (NAV) per share rose by 11 percent, while the share price advanced by 34 percent, thus significantly reducing the discount. It now stands at a little over ten percent.

The investment portfolio generated an increase in value of CHF 152.6 million net in the reporting period. This was held back to some extent by negative currency trends (CHF – 29 million), and the partial hedge of exchange-listed securities (CHF – 28 million).

In the portfolio of private companies, the valuation of Cathay Industrial Biotech was increased by CHF 43.3 million on the strength of its business performance and the resulting growth in revenue and profits. The takeovers of TandemLife (also known as Cardiac Assist) by LivaNova (CHF 28 million) and of True North Therapeutics by Bioverativ/Sanofi (CHF 9.5 million) also contributed substantially to profits. In addition, two IPOs – ARMO BioSciences (CHF 34.7 million) and Homology Medicines (CHF 6.5 million) resulted in significant increases in value.

Meanwhile, private company Vitaeris entered into a strategic partnership with CSL to develop the clazakizumab antibody. CSL is financing clinical trials, and in return received the option to purchase Vitaeris at a later point in time. In line with the prudent valuation policy of HBM Healthcare Investments, this deal had no immediate effect on the carrying value of this holding. However, there might be a significant increase in Vitaeris's valuation if the clinical trials are completed successfully and CSL exercises its purchase option.

Among the public companies, the holding in Advanced Accelerator Applications generated the largest single profit contribution, of CHF 105.2 million. The company was acquired by Novartis for USD 3.9 billion during the year under review. Other major contributions were generated by investments in AnaptysBio (CHF 33.4 million), Argenx (CHF 26.0 million), Esperion Therapeutics (CHF 19.6 million) and Neurocrine Biosciences (CHF 15.5 million).

Not everything went to plan, however. At Vectura Group there was a delay in approval for the generic version of Advair in the USA. The FDA is requesting additional study data from development partner Hikma; Hikma and Vectura now expect an approval in 2020. The news cut the value of the holding in Vectura by CHF 54.0 million during the reporting year. Meanwhile, the Pacira Pharmaceuticals share price came under pressure owing to mixed results from the phase III studies aimed at extending approval for its Exparel® pain relief drug to a further indication, nerve blockage. The value of the holding fell by CHF 17.6 million as a result. In February, the majority of an FDA Advisory Committee rejected extended approval, before the FDA granted it nonetheless in early April 2018, after which the share price recovered somewhat. The holdings in Tesaro (CHF – 19.9 million) and Nabriva Therapeutics (CHF – 18.0 million) also proved a drain on the annual result.

Management fees (CHF 14.2 million), the performance fee paid to the Investment Advisor (CHF 15.9 million) and the variable compensation for the Board of Directors (CHF 1.0 million) are in line with the increase in net assets and value growth that have been achieved.

The appendix to this media release is including the balance sheet and comprehensive income of the Group Annual Financial Statements IFRS, Portfolio details as well as an overview of the Consolidated Financials including translation to IFRS Group Financial Statements.

The detailed Annual Report 2017/2018 will be published on 1 June 2018 and will be available on the Company's website from then onwards.

Portfolio and new investments in private companies

A total of CHF 121 million was dedicated to new investments and follow-on financing rounds during the reporting year. Swiss company Amicus Ltd, which specialises in the sale of pharmaceutical products and medical devices in central and eastern Europe, received EUR 20 million.

USD 30 million was invested in US company Harmony Biosciences. Harmony acquired the US rights to Pitolisant for the treatment of narcolepsy in adults which has already been approved in Europe. The aim is to secure approval for the drug on the US market. Finally, USD 23 million went to Y-mAbs Therapeutics, which is developing a promising pipeline of immunotherapies to treat cancer in children.

In addition to these three major investments in companies with attractive risk profiles, HBM Healthcare Investments made ten smaller-scale investments of between CHF 2 million and CHF 8 million each in companies with promising clinical development programmes. It is to be expected that these companies will require further capital over time, and that the investment holdings will grow in line with the progress they make.

The portfolio of funds recorded a high level of return cash flows, totalling CHF 52 million. Capital payments into investment funds came to a total of CHF 23 million. Part of this liquidity was allocated to investment teams with a focus on China, via new investment commitments of USD 25 million to 6 Dimension Capital and of USD 5 million to BioVeda China IV. This further increases the proportion of the portfolio invested in this growing healthcare market.

All in all, the HBM Healthcare Investments portfolio remains well balanced: private companies (including funds and milestone payments) accounted for 38 percent of net assets, and public companies 65 percent (around one fifth of which is subject to a market hedge).

Cash dividend boosted by 20 percent

The Board of Directors is proposing to the Shareholders' Meeting that the cash dividend from the capital reserve be increased by CHF 1.20 per share (+ 20 percent) to a total of CHF 7.00 per share. Based on the share price at the end of the financial year, this corresponds to a distribution yield of 4.9 percent. Should the shareholders adopt the Board's proposals, CHF 5.50 per share will be paid out from the available capital reserve after the Shareholders' Meeting, before the end of June. This payment will almost exhaust the capital reserve. The Board of Directors is thus also proposing a reduction of CHF 30 in par value per share, in other words from CHF 58.50 to CHF 28.50 per share,

in order to replenish this reserve. This will ensure that, providing the business does well, HBM Healthcare Investments can continue to pursue its distribution policy of withholding tax-exempt cash dividends in the years to come. The remaining amount of CHF 1.50 per share will then be paid once the par value reduction has been completed, before the end of September 2018, from the newly increased capital reserve.

Outlook

The innovative drive and long-term growth prospects of the healthcare sector remain positive. HBM Healthcare Investments thus believes that mergers and acquisitions activity in the sector will continue at a high level. Tax reforms in the USA are likely to provide additional support for this.

The major holdings in the portfolio of private companies are developing positively, and the realisation of significant added value from these investments in the coming years as a result of IPOs or trade sales is expected.

HBM Healthcare Investments will make further new investments in private companies within the framework defined by the investment strategy. The focus is also on the fast-growing regions of Asia, where HBM Healthcare Investments will further increase its exposure.

A number of events that will have a bearing on the value of HBM Healthcare Investments – such as clinical study data and approval decisions – are expected for the portfolio of public companies. Volatility in the sector is expected to remain high and HBM Healthcare Investments will thus continue to hedge part of its market risk for the time being.

For further information, please contact Dr. Andreas Wicki on +41 41 710 75 77, andreas.wicki@hbmhealthcare.com

Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

HBM Healthcare Investments Ltd

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

Balance Sheet

Balance sheet (CHF 000)	Notes	31.3.2018	31.3.2017
Assets			
Current assets			
Cash and cash equivalents		6 522	6 115
Receivables		37	51
Total current assets		6 559	6 166
Non-current assets			
Investment in subsidiary	(3)	1 253 924	1 192 834
Total non-current assets		1 253 924	1 192 834
Total assets		1 260 483	1 199 000
Liabilities			
Current liabilities			
Liability from performance fee	(3.4)	1 018	1 413
Other liabilities		2 333	2 754
Total current liabilities		3 351	4 167
Non-current liabilities			
Financial liabilities	(4)	99 236	99 072
Total non-current liabilities		99 236	99 072
Shareholders' equity			
Share capital	(5.1)	411 840	427 050
Treasury shares	(5.2)	– 10 048	– 23 563
Capital reserve	(5.1)	185 318	237 362
Retained earnings		570 786	454 912
Total shareholders' equity		1 157 896	1 095 761
Total liabilities and shareholders' equity		1 260 483	1 199 000
Number of outstanding shares (in 000)		6 957	7 066
Net asset value (NAV) per share (CHF)		166.43	155.09

Comprehensive Income

Statement of comprehensive income for the financial year ended 31 March (CHF 000)	Notes	2017/2018	2016/2017
Dividend income from investment in subsidiary	(3)	60 000	80 000
Net change in value of investment in subsidiary	(3)	61 090	62 413
Result from investment activities		121 090	142 413
Personnel expenses	(6)	– 1 908	– 2 301
Other operating expenses		– 871	– 913
Result before interest and taxes		118 311	139 199
Financial expenses	(4)	– 2 438	– 2 428
Financial income		1	1
Income taxes		0	0
Net result for the year		115 874	136 772
Comprehensive result		115 874	136 772
Number of outstanding shares, time-weighted (in 000)		7 001	7 212
Basic earnings per share (CHF)		16.55	18.96

As the Company does not have options or similar instruments outstanding, diluted earnings per share are identical to basic earnings per share.

Investment in Subsidiary

The fair value of the investment in the Subsidiary HBM Healthcare Investments (Cayman) Ltd developed as follows in the year under review:

Development fair value investment (CHF 000)	2017/2018	2016/2017
Fair value at the beginning of financial year	1 192 834	1 130 421
Increase in value, gross	121 090	142 413
Dividend payment to parent company	– 60 000	– 80 000
Fair value at the end of financial year	1 253 924	1 192 834

Net assets of the investment in the Subsidiary comprised the following as at the balance sheet date:

Composition net assets (CHF 000)	31.3.2018	31.3.2017
Cash and cash equivalents	213 551	203 890
Receivables	393	363
Loan to parent company	0	0
Investments		
Private companies	288 365	122 491
Funds	125 579	151 762
Public companies	749 960	813 569
Shares of parent company	7 403	8 879
Financial instruments	3 121	9 001
Other financial assets	29 740	39 002
Total assets	1 418 112	1 348 957
Financial instruments	– 147 628	– 132 991
Liability from performance fee	– 15 942	– 22 135
Other current liabilities	– 618	– 997
Total net assets at fair value	1 253 924	1 192 834

During the reporting period, the net assets of the investment in the Subsidiary have developed as follows:

Change in net assets at fair value (CHF 000)	2017/2018	2016/2017
Net result on investments	190 868	155 625
Dividend income	140	178
Net result from financial instruments	– 33 938	2 571
Net result from other financial assets	– 6 515	17 932
Net result from shares of parent company	2 042	2 197
Result from investing activities	152 597	178 503
Management fee	– 14 229	– 12 675
Performance fee	– 15 942	– 22 135
Personnel and other operating expenses	– 1 369	– 1 158
Financial result	33	– 122
Increase in value, gross	121 090	142 413
Dividend payment to parent company	– 60 000	– 80 000
Net change in value of investment	61 090	62 413

Details on Investments

Private companies	Domicile	Investment currency	Amount disbursed 31.3.2017	Changes in reporting period	Amount disbursed 31.3.2018	Fair value 31.3.2018	Ownership 31.3.2018	Fair value 31.3.2018	Fair value 31.3.2017
		IC	IC million	IC million	IC million	IC million	%	CHF 000	CHF 000
Cathay Industrial Biotech	CN	USD	28.0		28.0	91.5	8.5	87 292	43 964
TandemLife (Cardiac Assist) ¹⁾	US	USD	4.4		4.4	32.6	16.6	31 148	3 145
Harmony Biosciences	US	USD	0.0	30.0	30.0	32.6	8.1	31 109	0
Amicus	CH	EUR	0.0	20.0	20.0	20.0	29.0	23 514	0
Y-mAbs Therapeutics	US	USD	0.0	23.2	23.2	23.2	8.2	22 176	0
Westmed Holding	US	USD	7.0		7.0	12.4	22.7	11 862	12 467
Vascular Dynamics	US	USD	9.0	1.0	10.0	10.0	13.8	9 505	9 005
Neurelis	US	USD	5.5	2.7	8.3	8.2	15.0	7 870	5 514
1mg	IN	INR	136.0	379.7	515.7	515.7	10.6	7 543	2 103
FarmaLatam	PA	USD	4.3	3.4	7.7	7.7	77.4	7 320	4 317
Aptinyx	US	USD	0.0	6.5	6.5	6.5	2.6	6 201	0
SAI Life Sciences	IN	INR	256.4		256.4	411.5	6.1	6 019	5 453
Formation Biologics	CA	CAD	0.0	6.5	6.5	6.5	10.0	4 771	0
Vitaeris	CA	USD	3.0		3.0	4.0	18.9	3 816	4 010
Valcare	US	USD	0.0	3.5	3.5	3.5	6.6	3 339	0
Shriji Polymers	IN	INR	0.0	201.0	201.0	216.2	2.8	3 163	0
Shape Memory Medical	US	USD	0.0	3.0	3.0	3.0	10.9	2 862	0
Complexa	US	USD	0.0	2.9	2.9	2.9	4.1	2 771	0
BaseHealth	US	USD	0.0	2.5	2.5	2.5	6.2	2 385	0
Amphora Medical	US	USD	0.0	2.2	2.2	2.2	5.5	2 074	0
Iconic Therapeutics	US	USD	7.5		7.5	1.9	7.1	1 789	3 760
True North Therapeutics ²⁾	US	USD	10.0	-10.0	0.0	0.0	0.0	0	10 026
Others								9 836	8 701
Total private companies								288 365	112 465

1) The company was acquired during the reporting period. The transaction was completed on April 4, 2018.

2) This investment was sold during the reporting period.

Funds	Investment currency	Total commitment	Payments in reporting period	Repayments in reporting period	Cumulative payments 31.3.2018	Cumulative repayments 31.3.2018	Fair value 31.3.2018	Fair value 31.3.2018	Fair value 31.3.2017
	IC	IC million	IC million	IC million	IC million	IC million	IC million	CHF 000	CHF 000
HBM BioCapital II ¹⁾	EUR	42.0	4.9	3.2	37.0	3.7	26.0	30 585	27 383
MedFocus Fund II	USD	16.0			16.0	15.0	18.8	17 971	19 497
WuXi Healthcare Ventures II	USD	20.0	2.0	0.4	13.0	0.6	13.6	12 974	11 891
6 Dimensions Capital	USD	25.0	13.0	0.0	13.0	0.0	12.8	12 243	0
Tata Capital HBM Fund I	USD	10.0	0.2		9.1	0.5	9.5	9 094	7 989
BioMedInvest II	CHF	10.0			10.0	1.8	8.8	8 840	8 360
Hatteras Venture Partners III	USD	10.0			10.0	2.0	8.6	8 250	9 997
HBM Genomics	USD	15.0	2.7		8.9	0.0	8.5	8 137	5 368
BioMedInvest I	CHF	26.0		3.1	26.0	24.6	7.0	6 994	10 400
Galen Partners V	USD	10.0	0.6	6.1	10.2	7.6	5.4	5 168	9 085
Nordic Biotech	DKK	31.0		209.9	31.0	221.7	17.8	2 781	31 634
BioVeda China	USD	8.5		4.6	8.5	31.8	0.0	0	5 398
Others								2 542	4 760
Total funds								125 579	151 762

1) The fair value of EUR 26.0 million takes into account the fund's cumulative management fees of EUR 4.8 million. This amount has been reimbursed in full to HBM Healthcare so that fees are not levied twice.

Public companies	Investment currency	Balance 31.3.2017	Changes in reporting period	Balance 31.3.2018	Share price 31.3.2018	Ownership 31.3.2018	Fair value 31.3.2018	Fair value 31.3.2017
	IC	Number of shares	Number of shares	Number of shares	IC	%	CHF 000	CHF 000
Vectura Group	GBP	67 991 719	-4 988 850	63 002 869	0.78	9.5	65 410	130 637
ARMO BioSciences ^{1) P)}	USD	809 800	781 740	1 591 540	37.41	5.2	56 801	10 026
Pacira Pharmaceuticals ^{P)}	USD	1 100 000	0	1 100 000	31.15	2.7	32 689	50 290
ObsEva ^{P)}	USD	2 319 780	-6 450	2 313 330	13.50	6.2	29 782	24 212
Galapagos	EUR	156 000	144 000	300 000	81.30	0.6	28 676	13 591
Genmab	DKK	182 800	-42 800	140 000	1 298.00	0.2	28 662	35 248
Esperion Therapeutics	USD	634 407	-234 407	400 000	72.33	1.5	27 601	22 459
Ascendis Pharma	USD	235 000	165 000	400 000	65.40	1.0	24 957	6 597
Ultragenyx Pharmaceutical	USD	384 257	115 743	500 000	50.99	1.0	24 322	26 113
Incyte	USD	205 000	45 000	250 000	83.33	0.1	19 874	27 474
AnaptysBio ^{P)}	USD	942 835	-742 835	200 000	104.08	0.8	19 858	26 232
Immunomedics	USD	0	1 400 000	1 400 000	14.61	0.8	19 513	0
Celgene	USD	11 000	216 000	227 000	89.21	0.0	19 319	1 372
Argenx (ADS)	USD	0	250 542	250 542	80.44	0.8	19 227	0
Argenx	EUR	255 000	-5 000	250 000	65.20	0.8	19 164	4 507
Nicox	EUR	1 184 941	488 363	1 673 304	9.07	5.7	17 844	12 418
Eagle Pharmaceuticals	USD	198 279	155 328	353 607	52.69	2.4	17 775	16 488
Neurocrine Biosciences	USD	529 500	-320 500	209 000	82.93	0.2	16 535	22 987
Homology Medicines ^{1) P)}	USD	0	902 794	902 794	18.70	2.5	16 106	0
Zogenix	USD	0	400 000	400 000	40.05	1.2	15 283	0
Acadia Pharmaceuticals	USD	144 990	555 010	700 000	22.47	0.6	15 005	4 998
Tesaro	USD	152 750	97 250	250 000	57.14	0.5	13 628	23 565
Amicus Therapeutics	USD	1 186 604	-341 820	844 784	15.04	0.5	12 121	8 482
AveXis	USD	62 000	38 000	100 000	123.58	0.3	11 790	4 726
Clovis	USD	0	230 105	230 105	52.80	0.5	11 591	0
Regenxbio	USD	546 000	-146 000	400 000	29.85	1.3	11 391	10 565
Nabryva Therapeutics ^{P)}	USD	2 968 980	-634 973	2 334 007	5.03	6.4	11 200	35 720
Paratek Pharmaceuticals ^{P)}	USD	1 200 000	-305 000	895 000	13.00	2.9	11 100	23 160
La Jolla Pharmaceutical	USD	0	355 000	355 000	29.78	1.4	10 086	0
Puma Biotechnology	USD	0	150 000	150 000	68.05	0.4	9 738	0
Divis Laboratories	INR	608 000	0	608 000	1 090.20	0.2	9 695	5 864
Arena Pharmaceuticals	USD	0	250 000	250 000	39.50	0.5	9 421	0
Retrophin	USD	0	433 952	433 952	22.36	1.1	9 257	0
Erytech Pharma	EUR	200 000	181 529	381 529	17.00	2.1	7 626	6 002
Albireo Pharma	USD	0	200 000	200 000	32.57	1.7	6 214	0
Coherus Biosciences	USD	582 442	-5 000	577 442	11.05	1.0	6 087	12 351
Bioarctic	SEK	0	2 271 809	2 271 809	21.40	3.1	5 560	0
Eiger BioPharmaceuticals ^{P)}	USD	603 819	-23 819	580 000	9.85	5.5	5 450	6 932
Apellis Pharmaceuticals	USD	0	250 000	250 000	22.11	0.5	5 273	0
Corium International	USD	118 404	345 474	463 878	11.47	1.3	5 076	496
Probiobdrug ^{P)}	EUR	497 910	-97 671	400 239	10.55	4.9	4 964	8 391
Medartis	CHF	0	70 000	70 000	70.50	0.6	4 935	0
Intercept Pharmaceuticals	USD	76 250	-1 250	75 000	61.52	0.3	4 402	8 646
RA Pharmaceuticals	USD	255 000	495 000	750 000	5.31	2.3	3 799	5 443
Spring Bank Pharmaceuticals	USD	0	258 736	258 736	15.38	2.0	3 796	0
Laurus Labs	INR	501 698	0	501 698	502.85	0.5	3 690	4 004
Novan	USD	0	1 294 400	1 294 400	2.93	5.0	3 618	0
Alimera Sciences	USD	3 250 000	250 000	3 500 000	1.03	5.0	3 439	4 562
Advanced Accelerator Applications ^{2) P)}	USD	3 300 000	-3 300 000	0	n/a	0.0	0	131 880
Others							10 610	87 157
Total public companies							749 960	823 595
Total investments							1 163 904	1 087 822

P) The position originates from the private companies portfolio.
1) The companies went public on NASDAQ in January and March 2018, respectively. The investments were listed under private companies in previous reports.

2) The company was acquired during the reporting period. HBM Healthcare sold all of its shares.

Balance Sheet

Balance sheet (CHF 000)	Notes to IFRS Group Financial Statements ¹⁾	Consolidated Financials ²⁾ 31.3.2018	Translation ³⁾	IFRS Group Financial Statements 31.3.2018
Assets				
Current assets				
Cash and cash equivalents		220 073	– 213 551	6 522
Receivables		430	– 393	37
Financial instruments	(3.2)	3 121	– 3 121	0
Total current assets		223 624	– 217 065	6 559
Non-current assets				
Investments	(3.1)	1 163 904	– 1 163 904	0
Other financial assets	(3.3)	29 740	– 29 740	0
Investment in subsidiary		0	1 253 924	1 253 924
Total non-current assets		1 193 644	60 280	1 253 924
Total assets		1 417 268	– 156 785	1 260 483
Liabilities				
Current liabilities				
Financial instruments	(3.2)	147 628	– 147 628	0
Liability from performance fee		16 960	– 15 942	1 018
Other liabilities		2 951	– 618	2 333
Total current liabilities		167 539	– 164 188	3 351
Non-current liabilities				
Financial liabilities	(4)	99 236	0	99 236
Total non-current liabilities		99 236	0	99 236
Shareholders' equity				
Share capital	(5.1)	411 840	0	411 840
Treasury shares	(5.2)	– 17 026	6 978	– 10 048
Capital reserve	(5.1)	189 849	– 4 531	185 318
Retained earnings		565 830	4 956	570 786
Total shareholders' equity		1 150 493	7 403	1 157 896
Total liabilities and shareholders' equity		1 417 268	– 156 785	1 260 483
Number of outstanding shares (in 000)		6 906	51	6 957
Net asset value (NAV) per share (CHF)		166.60		166.43

1) Details on the individual items can be found in the notes to the audited IFRS Group Financial Statements of the annual report.

2) Consolidated financials of the HBM Healthcare Group with full consolidation of the subsidiary HBM Healthcare Investments (Cayman) Ltd. and its subsidiary HBM Private Equity India Ltd, Republic of Mauritius.

3) Reconciliation to the audited IFRS Group Financial Statements. Based on IFRS 10, the subsidiary is no longer consolidated, but is valued individually at fair value through profit and loss. The differences in equity and net profit for the year result from the shares of the parent company held by the subsidiary. In the consolidated financial statements, these are deducted from equity at their acquisition cost. In the IFRS Group Financial Statements, they are valued at fair value through profit and loss by the subsidiary.

Comprehensive Income

Statement of comprehensive income for the financial year ended 31 March (CHF 000)	Notes to IFRS Group Financial Statements ¹⁾	Consolidated Financials ²⁾ 2017/2018	Translation ³⁾	IFRS Group Financial Statements 2017/2018
Net result on investments	(3.1)	190 868	– 190 868	0
Dividend income		140	– 140	0
Net result from financial instruments	(3.2)	– 33 938	33 938	0
Net result from other financial assets		– 6 515	6 515	0
Dividend income from investment in subsidiary		0	60 000	60 000
Net change in value of investment in subsidiary		0	61 090	61 090
Result from investment activities		150 555	– 29 465	121 090
Management fee	(3.4.1)	– 14 229	14 229	0
Performance fee	(3.4.2)	– 15 942	15 942	0
Personnel expenses	(6)	– 2 749	841	– 1 908
Other operating expenses		– 1 399	528	– 871
Result before interest and taxes		116 236	2 075	118 311
Financial expenses		– 2 438	0	– 2 438
Financial income		34	– 33	1
Income taxes		0	0	0
Net result for the year		113 832	2 042	115 874
Comprehensive result		113 832	2 042	115 874
Number of outstanding shares, time-weighted (in 000)		6 943	58	7 001
Basic earnings per share (CHF)		16.40		16.55

For the footnotes, see previous page.